0000911916-16-000693.txt : 20161201 0000911916-16-000693.hdr.sgml : 20161201 20161201164356 ACCESSION NUMBER: 0000911916-16-000693 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161201 FILED AS OF DATE: 20161201 DATE AS OF CHANGE: 20161201 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CoLucid Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348649 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203419541 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 781-365-2596 MAIL ADDRESS: STREET 1: 222 THIRD STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Colucid Pharmaceuticals Inc DATE OF NAME CHANGE: 20060104 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dallas Matthew D CENTRAL INDEX KEY: 0001612396 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37358 FILM NUMBER: 162028843 MAIL ADDRESS: STREET 1: AVEO PHARMACEUTICALS, INC. STREET 2: 650 EAST KENDALL STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2016-12-01 0001348649 CoLucid Pharmaceuticals, Inc. CLCD 0001612396 Dallas Matthew D C/O COLUCID PHARMACEUTICALS, INC. 222 THIRD STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Financial Officer Common Stock 2016-12-01 4 S 0 1473 35.1671 D 41601 D Securities sold pursuant to a written plan intended to comply with Rule 10b5-1(c)(i) adopted by Mr. Dallas on August 15, 2016. One purpose of the plan is to sell shares of common stock acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan. Represents the sale of 1,473 shares in multiple transactions, ranging in price from $35.00 to $35.45 per share, resulting in a weighted average sale price of $35.1671. The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range. Includes 5,574 shares acquired under the CoLucid Pharmaceuticals, Inc. Employee Stock Purchase Plan through November 30, 2016. /s/ Christine G. Long, Attorney-in-Fact for Matthew D. Dallas (power of attorney previously filed) 2016-12-01